Model‐informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Marzeptacog alfa (activated) (MarzAA) is an activated recombinant human rFVII variant intended for subcutaneous (s.c.) administration to treat or prevent bleeding in individuals with hemophilia A (HA) or B (HB) with inhibitors, and other rare bleeding disorders. The s.c. administration provides bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Faraj, Alan, van Wijk, Rob C., Neuman, Linda, Desai, Shraddha, Blouse, Grant E., Knudsen, Tom, Simonsson, Ulrika S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349190/
https://www.ncbi.nlm.nih.gov/pubmed/37042339
http://dx.doi.org/10.1002/psp4.12967

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349190/
https://www.ncbi.nlm.nih.gov/pubmed/37042339
http://dx.doi.org/10.1002/psp4.12967

Ejemplares similares